Hepatitis C
Conditions
Brief summary
Chronic viral hepatitis C is a public health problem and several management recommendations are available. According to the French High Authority of Health, hepatitis C screening consists of a targeted screening of people at risk of infection by the virus, in particular drug users, people from countries with a high prevalence of the virus or who have received care in those countries, people transfused before 1992, or people who are or have beenincarcerated . French government recommendations aim to achieve elimination of hepatitis C virus HCV (as early as 2025) and since April 2018 the European Hospital Marseille is engaged in this battle and organizes every year the day without hepatitis in the hospital. Since 2017, direct-acting antiviral treatments have become available in France to all patients infected with HCV, regardless of the degree of severity of their disease. These treatments are effective in more than 95% of cases and, in 2019, 18,000 people were cured. As of today, it is estimated that there are still 110,000 people likely to be treated in France. Among them, 75,000 are unaware of being HCV positive, people who need to be tested. With one of the largest volumes of digestive endoscopic examinations in France, the European Hospital Marseille may be a significant source of screening for hepatitis C. Our study proposes to evaluate hepatitis C screening in consenting patients hospitalized in the endoscopy department at the European Hospital Marseille.
Interventions
DIAGNOSTIC_TESTRapid diagnostic orientation test (TROD) for Hepatitis C
Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
Sponsors
Hôpital Européen Marseille
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Inclusion criteria
* Aged ≥ 50 * Giving free and informed written consent * Being affiliated with or benefiting from a social security scheme
Exclusion criteria
\- Patient unable to express consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients aged 50 and over tested positive for chronic viral hepatitis C during gastrointestinal endoscopy. | 16 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients who refuse viral screening | 16 months |
| Investigation and identification of potential risk factors in patients diagnosed positive for chronic viral hepatitis C | 16 months |
| Number of viremic patients without risk factor | 16 months |
Countries
France
Contacts
Primary ContactMyriam BENNANI
Outcome results
None listed